Default company panoramic image
F09ecc6f 10f1 40d8 8218 2adbf781dfe9

DeNovo Sciences

Our mission is to develop and sell integrated platforms that accelerate cancer discoveries and the early detection of metastasis.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Plymouth, MI, USA
  • Currency USD
  • Employees 4
  • Website denovosciences.com

Company Summary

DeNovo Sciences is committed to the development and sale of an integrated platform that improves cancer research, diagnosis and treatment by capturing rare circulating tumor cells from a simple blood-draw. This technology will allow patients to avoid undergoing painful biopsies, and provide clinicians with important information regarding the selection of treatment courses and patient prognosis.

Team

  • Default avatar
    Kalyan Handique, Ph.D.
    Chief Executive Officer

    Co-founder, CTO & Board Member of Handyab (acquired by BD for $275MM); 11+ years commercialization experience in microfluidics, molecular diagnostics and IVD; VP at BD diagnostics (2009-11).

  • Default avatar
    Roger Newton, Ph.D.
    Business Adviser

    Currently the Founder, President and CEO of Esperion Therapeutics; 27+ years pharmaceutical and life science experience; Founder of Esperion I (acquired by Pfizer for $1.3 Billion); Co-discovered (Lipitor®) while a distinguished scientist at Warner Lambert/Parke-Davis (now Pfizer)

  • Default avatar
    Mark Powelson, MBA
    Business Adviser (Management in waiting--Sales and Marketing)

    25 years of sales and marketing for HandyLab, Boehringer Manheim/Roche Diagnostics, Chiron Diagnostics, and Eli Lily

  • Default avatar
    Steve Richvalsky
    Business Adviser (Management in waiting--CFO)

    25 years of CFO for BD Ann Arbor, HandyLab, Genomic Solutions and Ardesta

  • Default avatar
    Ramzi Mohammad, Ph.D.
    Scientific Adviser/Collaborator

    Director, Oncology, Karmanos Cancer Institute, 30 years in cancer research